Ernexa Therapeutics Inc. Indefinite-lived Intangible Assets, Period Increase (Decrease)
Ernexa Therapeutics Inc. (ERNA) reported Indefinite-lived Intangible Assets, Period Increase (Decrease) of -$35.00 thousand for the 12-month period ending 2010-12-31, per its 10-K filed 2012-03-30.
Discontinued › Notes › Goodwill and Other
us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease · last filed 2012-03-30
- Ernexa Therapeutics Inc. indefinite-lived intangible assets, period increase (decrease) for the quarter ending 2010-12-31 was $0.00.
- Ernexa Therapeutics Inc. indefinite-lived intangible assets, period increase (decrease) for the quarter ending 2010-09-30 was $0.00.
- Ernexa Therapeutics Inc. indefinite-lived intangible assets, period increase (decrease) for fiscal 2010 was -$35.00K.
| Period end | Indefinite-lived Intangible Assets, Period Increase (Decrease) 3 month | Indefinite-lived Intangible Assets, Period Increase (Decrease) 6 month | Indefinite-lived Intangible Assets, Period Increase (Decrease) 9 month | Indefinite-lived Intangible Assets, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30 | $0.00 derived: sum of 2 quarters · filed 2012-03-30 | -$35.00K 10-K · filed 2012-03-30 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | -$35.00K 10-Q · filed 2011-11-14 | ||
| 2010-06-30 | -$35.00K 10-Q · filed 2011-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |